WWWei Wei
Wei Wei
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wei Wei has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Chuanchun Han
Institute of Cancer Stem Cell, DalianMedical University, Dalian 116044, PR China
2 shared publicationsXintong Kui
The First Affiliated Hospital, Dalian Medical University, Dalian 116044, PR China
2 shared publications- Chuanchun Han
Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China
1 shared publication Chunhao He
The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning 116044, PR China
1 shared publicationJia Zhu
Institute of Cancer Stem Cells, Dalian Medical University, Dalian, Liaoning 116044, PR China
1 shared publicationJiaxin Liu
Institute of Cancer Stem Cell, DalianMedical University, Dalian 116044, PR China
1 shared publication
Latest Publications
- Open Access
- 30 May 2026
- Published by Elsevier in Journal of Advanced Research
Rhein suppresses lactate metabolism and melanoma progression via downregulating LDHA/H3K18 lactylation/PLK1 axis
- 30 May 2026
- Published by Elsevier in Journal of Advanced Research
Open AccessRhein suppresses lactate metabolism and melanoma progression via downregulating LDHA/H3K18 lactylation/PLK1 axis
- 18 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 241, 117182
Targeting BACH1/PSPH axis suppresses bladder cancer progression and gemcitabine resistance by downregulating S100A2 expression
- 18 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 241, 117182
Targeting BACH1/PSPH axis suppresses bladder cancer progression and gemcitabine resistance by downregulating S100A2 expression
- 15 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 241, 117152
Rhein suppresses osteosarcoma progression via modulating the miR-328-3p/TCF7L2/FABP4 axis
- 15 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 241, 117152
Rhein suppresses osteosarcoma progression via modulating the miR-328-3p/TCF7L2/FABP4 axis